MyMedR

Displaying all 4 publications

Abstract:

Sort:

The AfrAbia+plus Parkinson's Disease Genomic Consortium

Mohamed W, Eltantawi MA, Mecheri Y, Zewde YZ, Kamel WA, Al-Mubarak BR, et al.

Lancet Neurol, 2024 Feb;23(2):140-141.
PMID: 38267182 DOI: 10.1016/S1474-4422(23)00453-2
Fulltext Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide

Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al.

Front Neurol, 2020;11:501.
PMID: 32670177 DOI: 10.3389/fneur.2020.00501

Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon inflammatory disease of the central nervous system, manifesting clinically as optic neuritis, myelitis, and certain brain and brainstem syndromes. Cases clinically diagnosed as NMOSD may include aquaporin 4 (AQP4)-antibody-seropositive autoimmune astrocytopathic disease, myelin oligodendrocyte glycoprotein (MOG)-antibody-seropositive inflammatory demyelinating disease, and double-seronegative disease. AQP4-antibody disease has a high female-to-male ratio (up to 9:1), and its mean age at onset of ~40 years is later than that seen in multiple sclerosis. For MOG-antibody disease, its gender ratio is closer to 1:1, and it is more common in children than in adults. Its clinical phenotypes differ but overlap with those of AQP4-antibody disease and include acute disseminated encephalomyelitis, brainstem and cerebral cortical encephalitis, as well as optic neuritis and myelitis. Double-seronegative disease requires further research and clarification. Population-based studies over the past two decades report the prevalence and incidence of NMOSD in different populations worldwide. One relevant finding is the varying prevalence observed in different racial groups. Consistently, the prevalence of NMOSD among Whites is ~1/100,000 population, with an annual incidence of <1/million population. Among East Asians, the prevalence is higher, at ~3.5/100,000 population, while the prevalence in Blacks may be up to 10/100,000 population. For MOG-antibody disease, hospital-based studies largely do not observe any significant racial preponderance so far. This disorder comprises a significant proportion of NMOSD cases that are AQP4-antibody-seronegative. A recent Dutch nationwide study reported the annual incidence of MOG-antibody disease as 1.6/million population (adult: 1.3/million, children: 3.1/million). Clinical and radiological differences between AQP4-antibody and MOG-antibody associated diseases have led to interest in the revisions of NMOSD definition and expanded stratification based on detection of a specific autoantibody biomarker. More population-based studies in different geographical regions and racial groups will be useful to further inform the prevalence and incidence of NMOSD and their antibody-specific subgroups. Accessibility to AQP4-antibody and MOG-antibody testing, which is limited in many centers, is a challenge to overcome. Environmental and genetic studies will be useful accompaniments to identify other potential pathogenetic factors and specific biomarkers in NMOSD.
The Genetic Architecture of Parkinson's Disease in the AfrAbia Population: Current State and Future Perspectives

Mohamed W, Eltantawi MA, Agarwal V, Bandres-Ciga S, Makarious MB, Mecheri Y, et al.

J Integr Neurosci, 2024 Aug 19;23(8):152.
PMID: 39207075 DOI: 10.31083/j.jin2308152

Over 80% of genetic studies in the Parkinson's disease (PD) field have been conducted on individuals of European descent. There is a social and scientific imperative to understand the genetic basis of PD across global populations for therapeutic development and deployment. PD etiology is impacted by genetic and environmental factors that are variable by ancestry and region, emphasising the need for worldwide programs to gather large numbers of patients to identify novel candidate genes and risk loci involved in disease. Only a handful of documented genetic assessments have investigated families with PD in AfrAbia, which comprises the member nations of the Arab League and the African Union, with very limited cohort and case-control studies reported. This review article summarises prior research on PD genetics in AfrAbia, highlighting gaps and challenges. We discuss the etiological risk spectrum in the context of historical interactions, highlighting allele frequencies, penetrance, and the clinical manifestations of known genetic variants in the AfrAbian PD patient community.
Fulltext Clinicians' perspectives on complementary and alternative medicine use in headache care across Africa and West Asia: a cross-sectional survey

Hassan A, Dodd-Glover F, Magdy R, Ӧzge A, Uludüz D, Kissani N, et al.

Front Neurol, 2026;17:1849417.
PMID: 42947770 DOI: 10.3389/fneur.2026.1849417

BACKGROUND: Headache disorders impose a substantial burden across Africa and West Asia, where limited access to healthcare may increase reliance on complementary and alternative medicine (CAM). The current study explored clinicians' perspectives on CAM use, safety concerns, and research needs across countries with different income status.
METHODS: A cross-sectional web-based survey of 123 neurologists and headache specialists with at least 5 years of experience in headache management from 37 countries was carried out. They were classified into Low/Lower-Middle Income Countries (LIC/LMIC) and Upper-Middle Income Countries/High Income Countries (UMIC/HIC) groups in accordance with the World Bank income classifications.
RESULTS: Of 123 participants (median age 42 years; 50.4% males), 52.8% were from LICs/LMICs. Clinicians reported that CAMs were frequently used in both groups, and there was no significant difference in overall frequency of CAM use (p = 0.116). Clinicians in both groups perceived migraine as the most common headache type for which patients used CAM. However, significant differences in CAM modalities were observed. Acupuncture (79.3% vs. 47.7%, p